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Preamble
The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the benefits and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to a
thorough review of evidence has resulted in the production
of clinical practice guidelines that assist physicians in select-
ing the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a foun-
dation for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) havejointly produced guidelines in the area of cardiovascular
disease since 1980. The ACCF/AHA Task Force on
Practice Guidelines (Task Force), charged with developing,
updating, and revising practice guidelines for cardiovascular
diseases and procedures, directs and oversees this effort. Writ-
ing committees are charged with regularly reviewing and
evaluating all available evidence to develop balanced, patient-
centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a literature review; weigh
he strength of evidence for or against particular tests,
reatments, or procedures; and include estimates of ex-
ected outcomes where such data exist. Patient-specific
odifiers, comorbidities, and issues of patient preference
hat may influence the choice of tests or therapies are consid-
red. When available, information from studies on cost is
onsidered, but data on efficacy and outcomes constitute the
primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1). The
Class of Recommendation (COR) is an estimate of the size
of the treatment effect, with consideration given to risks
versus benefits in addition to evidence and/or agreement
that a given treatment or procedure is or is not useful/
effective or in some situations may cause harm. The Level of
Evidence (LOE) is an estimate of the certainty or precision
of the treatment effect. The writing committee reviews and
ranks evidence supporting each recommendation, with the
weight of evidence ranked as LOE A, B, or C according to
specific definitions that are included in Table 1. Studies are
identified as observational, retrospective, prospective, or
randomized as appropriate. For certain conditions for which
inadequate data are available, recommendations are based
on expert consensus and clinical experience and are ranked
as LOE C. When recommendations at LOE C are sup-
ported by historical clinical data, appropriate references
(including clinical reviews) are cited if available. For issues
for which sparse data are available, a survey of current
practice among the clinicians on the writing committee is
the basis for LOE C recommendations, and no references
are cited. The schema for COR and LOE is summarized in
Table 1, which also provides suggested phrases for writing
recommendations within each COR. A new addition to this
methodology is separation of the Class III recommendations to
delineate whether the recommendation is determined to be of
“no benefit” or is associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested phrases
for writing recommendations for the comparative effectiveness
of one treatment or strategy versus another have been added for
COR I and IIa, LOE A or B only.
(
A
C
Level o
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spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
GDMT) to represent optimal medical therapy as defined by
CCF/AHA guideline-recommended therapies (primarily
lass I). This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address
patient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing committee reviews the
Table 1. Applying Classification of Recommendations and Leve
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak
Although randomized trials are unavailable, there may be a very clear clinical consensus that a
Data available from clinical trials or registries about the usefulness/efficacy in different subp
failure, and prior aspirin use. †For comparative effectiveness recommendations (Class I and IIa;
comparisons of the treatments or strategies being evaluated.potential influence of different practice patterns and patientpopulations on the treatment effect and relevance to the
ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by describing a
range of generally acceptable approaches to the diagnosis,
management, and prevention of specific diseases or conditions.
The guidelines attempt to define practices that meet the needs
of most patients in most circumstances. The ultimate judg-
ment about care of a particular patient must be made by the
healthcare provider and patient in light of all the circumstances
presented by that patient. As a result, situations may arise in
which deviations from these guidelines might be appropriate.
vidence
important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
lar test or therapy is useful or effective.
ons, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
f Evidence A and B only), studies that support the use of comparator verbs should involve directl of E
. Many
particu
opulatiClinical decision making should involve consideration of the
S
t
c
f
c
a
E
G
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provided. When these guidelines are used as the basis for
regulatory or payer decisions, the goal should be improvement
in quality of care. The Task Force recognizes that situations
arise in which additional data are needed to inform patient care
more effectively; these areas will be identified within each
respective guideline when appropriate.
Prescribed courses of treatment in accordance with
these recommendations are effective only if followed.
Because lack of patient understanding and adherence may
adversely affect outcomes, physicians and other health-
care providers should make every effort to engage the
patient’s active participation in prescribed medical regi-
mens and lifestyles. In addition, patients should be
informed of the risks, benefits, and alternatives to a
particular treatment and should be involved in shared
decision making whenever feasible, particularly for COR IIa
and IIb, for which the benefit-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as
a result of industry relationships or personal interests among
the members of the writing committee. All writing com-
mittee members and peer reviewers of this guideline were
required to disclose all such current healthcare-related
relationships, as well as those existing 24 months (from
2005) before initiation of the writing effort. The writing
committee chair may not have any relevant relationships
with industry or other entities (RWI); however, RWI are
permitted for the vice chair position. In December 2009, the
ACCF and AHA implemented a new policy that requires a
minimum of 50% of the writing committee have no relevant
RWI; in addition, the disclosure term was changed to 12
months before writing committee initiation. The present
guideline was developed during the transition in RWI
policy and occurred over an extended period of time. In the
interest of transparency, we provide full information on
RWI existing over the entire period of guideline develop-
ment, including delineation of relationships that expired
more than 24 months before the guideline was finalized.
This information is included in Appendix 1. These state-
ments are reviewed by the Task Force and all members
during each conference call and meeting of the writing
committee and are updated as changes occur. All guideline
recommendations require a confidential vote by the writing
committee and must be approved by a consensus of the
voting members. Members who recused themselves from
voting are indicated in the list of writing committee mem-
bers, and section recusals are noted in Appendix 1. Authors’
and peer reviewers’ RWI pertinent to this guideline are
disclosed in Appendixes 1 and 2, respectively. Comprehen-
sive disclosure information for the Task Force is also
available online at http://www.cardiosource.org/ACC/
About-ACC/Who-We-Are/Leadership/Guidelines-and-
Documents-Task-Forces.aspx. The work of the writing
committee is supported exclusively by the ACCF, AHA,
American College of Physicians (ACP), American Associ-ation for Thoracic Surgery (AATS), Preventive Cardiovascular
Nurses Association (PCNA), Society for Cardiovascular An-
giography and Interventions (SCAI), and Society of Thoracic
urgeons (STS), without commercial support. Writing commit-
ee members volunteered their time for this activity.
The recommendations in this guideline are considered
urrent until they are superseded by a focused update or the
ull-text guideline is revised. The reader is encouraged to
onsult the full-text guideline (2) for additional guidance
nd details about stable ischemic heart disease since the
xecutive Summary contains only the recommendations.
uidelines are official policy of both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Overview
The recommendations listed in this document are, when-
ever possible, evidence based. An extensive evidence review
was conducted as the document was compiled through
December 2008. Repeated literature searches were per-
formed by the guideline development staff and writing
committee members as new issues were considered. When
available, current and credible meta-analyses were used
instead of conducting a systematic review of all primary
literature. New clinical trials published in peer-reviewed
journals and articles through December 2011 were also
reviewed and incorporated when relevant. Furthermore,
because of the extended development time period for this
guideline, peer review comments indicated that the sections
focused on imaging technologies required additional updat-
ing, which occurred during 2011. Therefore, the evidence
review for the imaging sections includes published literature
through December 2011.
Searches were limited to studies, reviews, and other
evidence in human subjects and published in English.
Key search words included, but were not limited to:
accuracy, angina, asymptomatic patients, cardiac magnetic
resonance (CMR), cardiac rehabilitation, chest pain, chronic
angina, chronic coronary occlusions, chronic ischemic heart
disease (IHD), chronic total occlusion, connective tissue
disease, coronary artery bypass graft (CABG) versus medical
therapy, coronary artery disease (CAD) and exercise, coro-
nary calcium scanning, cardiac/coronary computed tomogra-
phy angiography (CCTA), CMR angiography, CMR imag-
ing, coronary stenosis, death, depression, detection of CAD in
symptomatic patients, diabetes, diagnosis, dobutamine stress
echocardiography, echocardiography, elderly, electrocardio-
gram (ECG) and chronic stable angina, emergency depart-
ment, ethnic, exercise, exercise stress testing, follow-up test-
ing, gender, glycemic control, hypertension, intravascular
ultrasound, fractional flow reserve, invasive coronary an-
giography, kidney disease, low-density lipoprotein lowering,
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minority groups, mortality, myocardial infarction (MI),
noninvasive testing and mortality, nuclear myocardial per-
fusion, nutrition, obesity, outcomes, patient follow-up, pa-
tient education, prognosis, proximal left anterior descending
(LAD) disease, physical activity, reoperation, risk stratifica-
tion, smoking, stable ischemic heart disease (SIHD), stable
angina and reoperation, stable angina and revasculariza-
tion, stress echocardiography, radionuclide stress testing,
stenting versus CABG, unprotected left main, weight reduc-
tion, and women.
1.2. Organization of the Writing Committee
The writing committee was composed of physicians, car-
diovascular interventionalists, surgeons, general internists,
imagers, nurses, and pharmacists. The writing committee
included representatives from the ACP, AATS, PCNA,
SCAI, and STS.
1.3. Document Review and Approval
This document was reviewed by 2 external reviewers nom-
inated by both the ACCF and the AHA; 2 reviewers
nominated by the ACP, AATS, PCNA, SCAI, and STS;
and 19 content reviewers, including representatives from the
ACCF Imaging Council, ACCF Interventional Scientific
Council, and the AHA Council on Clinical Cardiology. All
reviewer RWI information was collected and distributed to
the writing committee and is published in this document
(Appendix 2). Because extensive peer review comments re-
sulted in substantial revision, the guideline was subjected to a
second peer review by all official and organizational reviewers.
Asymptomatic 
Persons 
Without 
Known IHD
(CV Risk)
Noncardiac 
Chest Pain
New Onset 
Chest Pain
(SIHD; UA/NSTEMI; STEMI)
Sudden Car
(VA-S
Noninvasive
Testing
*Features of low risk
•Age, 70 y
•Exertional pain la
•Pain not rapidly a
•Normal or unchan
•No elevation of ca
Figure 1. Spectrum of IHD
Guidelines relevant to the spectrum of IHD are in parentheses.
CABG indicates coronary artery bypass graft; CV, cardiovascular; ECG, electrocardiog
cardiac death; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarc
dial infarction; and VA, ventricular arrhythmia.Lastly, the imaging sections were also peer reviewed separately,
after an update to that evidence base.
This document was approved for publication by the
governing bodies of the ACCF, AHA, ACP, AATS,
PCNA, SCAI, and STS.
1.4. Scope of the Guideline
These guidelines are intended to apply to adult patients with
stable known or suspected IHD, including new-onset chest
pain (i.e., low-risk unstable angina [UA]), or to adult
patients with stable pain syndromes (Figure 1). Patients
who have “ischemic equivalents,” such as dyspnea or arm
pain with exertion, are included in the latter group. Many
patients with IHD can become asymptomatic with appro-
priate therapy. Accordingly, the follow-up sections of this
guideline pertain to patients who were previously symptom-
atic, including those who have undergone percutaneous
coronary intervention (PCI) or CABG.
This guideline also addresses the initial diagnostic approach
to patients who present with symptoms that suggest
IHD, such as anginal-type chest pain, but who are not
known to have IHD. In this circumstance, it is essential
that the practitioner ascertain whether such symptoms
represent the initial clinical recognition of chronic stable
angina, reflecting gradual progression of obstructive CAD or
an increase in supply/demand mismatch precipitated by a
change in activity or concurrent illness (such as anemia or
infection), or whether they represent an acute coronary
syndrome (ACS), most likely due to an unstable plaque
causing acute thrombosis. For patients with newly diagnosed
Asymptomatic
(SIHD)
Stable Angina 
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(SIHD; PCI/CABG)
Acute Coronary 
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acute MI, the reader is referred to the ACCF/AHA guidelines
for the management of patients with ST-elevation MI (3,4),
and for patients with UA, the reader is referred to the
“ACCF/AHA Guidelines for the Management of Patients
With Unstable Angina/Non–ST-Elevation Myocardial In-
farction” (5,5a). There are, however, patients with UA who can
be categorized as low risk and are addressed in this guideline
(Table 2).
A key premise of this guideline is that once a diagnosis of
IHD is established, it is necessary in most patients to assess
their risk of subsequent complications, such as acute myo-
cardial infarction or death. Because the approach to diag-
nosis of suspected IHD and the assessment of risk in a
patient with known IHD are conceptually different and are
based on different literature, these issues are addressed
separately. A clinician might, however, select a procedure for
a patient with a moderate to high pretest likelihood of IHD to
provide information for both diagnosis and risk assessment,
whereas in a patient with a low likelihood of IHD, it could be
sensible to select a test simply for diagnostic purposes without
regard to risk assessment. The purpose of this dichotomy is to
promote the sensible application of appropriate testing rather
than routine use of the most expensive or complex tests
whether warranted or not.
Table 2. Short-Term Risk of Death or Nonfatal MI in Patients W
Feature
High Risk
At least 1 of the following features must
be present:
No h
istory Accelerating tempo of ischemic symptoms
in preceding 48 h
Prior
or
Prior
haracteristics of pain Prolonged ongoing (20 min) rest pain Prolo
wi
Rest
su
Noct
New-
an
(
hig
Clinical findings Pulmonary edema, most likely due to
ischemia
New or worsening mitral regurgitation
murmur
S3 or new/worsening rales
Hypotension, bradycardia, or tachycardia
Age 75 y
Age
CG Angina at rest with transient ST-segment
changes 0.5 mm
Bundle-branch block, new or presumed new
Sustained ventricular tachycardia
T-wa
Path

inf
ardiac markers Elevated cardiac TnT, TnI, or CK-MB
(i.e., TnT or TnI 0.1 ng/mL)
Sligh
(i.
Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA or NSTE
the table is meant to offer general guidance and illustration rather than rigid algorithms.
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian
infarction; NTG, nitroglycerin; N/A, not available; TnI, troponin I; TnT, troponin T; and UA/NSTEMI, uns
Modified from Braunwald et al. (7).Additionally, this guideline addresses the approach to
asymptomatic patients with SIHD that has been diagnosed
solely on the basis of an abnormal screening study, rather than
on the basis of clinical symptoms or events such as anginal
symptoms or ACS. Multiple ACCF/AHA guidelines and
scientific statements have discouraged the use of ambulatory
monitoring, treadmill testing, stress echocardiography, stress
myocardial perfusion imaging (MPI), and computed tomog-
raphy scoring of coronary calcium or coronary angiography as
routine screening tests in asymptomatic individuals.
When patients with documented IHD develop recurrent
chest pain, the symptoms still could be attributable to
another condition. Such patients are included in this guide-
line if there is sufficient suspicion that their heart disease is
a likely source of symptoms to warrant cardiac evaluation.
Just as in the case of patients with new-onset chest pain, if
the pain seems to be cardiac in origin, the clinician must
determine whether such recurrent or worsening pain is
consistent with ACS or simply represents symptoms more
consistent with chronic stable angina that do not require
emergent attention.
The approach to screening and management of asymp-
tomatic patients who are at risk for IHD but who are not
known to have IHD is beyond the scope of this guideline,
but it is addressed in the “ACCF/AHA Guideline for
A/NSTEMI
Intermediate Risk Low Risk
sk features are present, but patient
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No high- or intermediate-risk
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Adults” (6). Similarly, the present guideline does not
apply to patients with chest pain symptoms early after
revascularization, that is, within 6 months of revascular-
ization.
1.5. General Approach and Overlap With
Other Guidelines or Statements
This guideline overlaps with numerous clinical practice
guidelines published by the ACCF/AHA Task Force on
Practice Guidelines; the National Heart, Lung, and Blood
Institute; and the ACP (Table 3). To maintain consistency,
the writing committee worked with members of other
committees to harmonize recommendations and eliminate
discrepancies.
This document recommends a combination of lifestyle
modifications and medications that constitute GDMT.
Recommendations for risk reduction are consistent with the
“AHA/ACCF Secondary Prevention and Risk Reduction
Therapy for Patients With Coronary and Other Vascular
Disease: 2011 Update” (8). Recommendations related to
revascularization are the result of collaboration discussions
among several writing committees, including those address-
ing SIHD, PCI, CABG, and unstable angina/non–ST-
elevation MI. To the fullest extent possible, these guidelines
are consistent with the appropriate use criteria documents
for imaging testing, diagnostic catheterization, and coronary
revascularization that are also sponsored by the ACCF
(9–14).
1.6. Magnitude of the Problem
It is estimated that 1 in 3 adults in the United States (about
71 million) has some form of cardiovascular disease, includ-
ing 13 million with CAD and nearly 9 million with
angina pectoris (26,27). Among persons 60 to 79 years of
Table 3. Associated Guidelines and Statements
Document
uidelines
Chronic Stable Angina: 2007 Focused Update
Valvular Heart Disease
Heart Failure: 2009 Update
STEMI
Assessment of Cardiovascular Risk in Asymptomatic Adults
Coronary Artery Bypass Graft Surgery
Percutaneous Coronary Intervention
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary
Other Atherosclerotic Vascular Disease
UA/NSTEMI: 2007 and 2012 Updates
tatements
NCEP ATP III Implications of Recent Clinical Trials
National Hypertension Education Program (JNC VII)
Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Preven
Clinical Centers and Beyond: A Presidential Advisory From the AHAACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; ATP I
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NHLBI, National Heart, Luage, approximately 23% of men and 15% of women have
prevalent IHD, and these figures rise to 33% and 22%
among men and women 80 years of age, respectively (27).
Although the survival rate of patients with IHD has been
steadily improving (28), it was still responsible for nearly
380,000 deaths in the United States in 2010, with an
age-adjusted mortality rate of 113 per 100,000 population
(29). Although IHD is widely known to be the number 1
cause of death in men, this is also the case for women,
among whom this condition accounts for 27% of deaths
(compared with 22% due to cancer) (30). IHD also accounts
for the vast majority of the mortality and morbidity of
cardiac disease. Each year, 1.5 million patients have an
I. Many more are hospitalized for UA and evaluation and
reatment of stable chest pain syndromes. Patients who have
ad ACS, such as acute MI, remain at risk for recurrent
vents even if they have no, or limited, symptoms, and they
hould be considered to have SIHD.
In approximately 50% of patients, angina pectoris is the
nitial manifestation of IHD (27). The incidence of angina
ises continuously with age in women, whereas the inci-
ence of angina in men peaks between 55 and 65 years of
ge before declining (27). It has been estimated that there
re 30 patients with stable angina for every patient hospi-
alized with infarction, and symptoms in many of these
atients are poorly controlled (31–33). The direct and
ndirect costs of caring for patients with IHD are estimated
o exceed $150 billion in the United States.
1.7. Organization of the Guideline
The overarching framework adopted in this guideline re-
flects the complementary goals of treating patients with
known SIHD, alleviating or improving symptoms, and
prolonging life. This guideline is divided into 4 basic
Reference(s) Organization
Publication
Year
(15) ACCF/AHA 2007
(16) ACCF/AHA 2008
(17) ACCF/AHA 2009
(3,4,18) ACCF/AHA 2009
(6) ACCF/AHA 2010
(19) ACCF/AHA 2011
(20) ACCF/AHA/SCAI 2011
(8) AHA/ACCF 2011
(5,5a) ACCF/AHA 2012
(22,23) NHLBI 2004
(24) NHLBI 2004
rograms at (25) AHA 2011and
tion PII, Adult Treatment Panel 3; JNC VII, The Seventh Report of the Joint National Committee on
ng and Blood Institute; and SCAI, Society for Cardiovascular Angiography and Interventions.
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assessment, treatment, and follow-up summarized in 5
algorithms: diagnosis (Figure 2), risk assessment (Figure 3),
GDMT (Figure 4), and revascularization (Figures 5 and 6).
n clinical practice, steps delineated in the algorithms often
verlap. An essential principle that transcends all recommen-
ations in this guideline is that of informing and involving
atients in all decisions that affect them, directly or indirectly,
s summarized in the following recommendation:
1.8. Vital Importance of Involvement by an
Informed Patient: Recommendation
CLASS I
1. Choices about diagnostic and therapeutic options should be made
through a process of shared decision making involving the patient
and provider, with the provider explaining information about risks,
benefits, and costs to the patient. (Level of Evidence: C)
2. Diagnosis of SIHD: Recommendations
2.1. Clinical Evaluation of Patients With Chest Pain
2.1.1. Clinical Evaluation in the Initial Diagnosis of
SIHD in Patients With Chest Pain
CLASS I
1. Patients with chest pain should receive a thorough history and
physical examination to assess the probability of IHD before addi-
tional testing (34). (Level of Evidence: C)
2. Patients who present with acute angina should be categorized as
stable or unstable; patients with UA should be further categorized as
being at high, moderate, or low risk (5,5a). (Level of Evidence: C)
2.1.2. Electrocardiography
2.1.2.1. RESTING ELECTROCARDIOGRAPHY TO ASSESS RISK
CLASS I
1. A resting ECG is recommended in patients without an obvious,
noncardiac cause of chest pain (36–38). (Level of Evidence: B)
2.1.3. Stress Testing and Advanced Imaging for Initial
Diagnosis in Patients With Suspected SIHD Who
Require Noninvasive Testing
See Table 4 for a summary of recommendations from this
ection.
2.1.3.1. ABLE TO EXERCISE
CLASS I
1. Standard exercise ECG testing is recommended for patients with an
intermediate pretest probability of IHD who have an interpretable
ECG and at least moderate physical functioning or no disabling
comorbidity (39–42). (Level of Evidence: A)
. Exercise stress with nuclear MPI or echocardiography is recom-
mended for patients with an intermediate to high pretest probability
of IHD who have an uninterpretable ECG and at least moderate
physical functioning or no disabling comorbidity (43–53). (Level of
Evidence: B)
CLASS IIa
1. For patients with a low pretest probability of obstructive IHD who dorequire testing, standard exercise ECG testing can be useful, providedthe patient has an interpretable ECG and at least moderate physical
functioning or no disabling comorbidity. (Level of Evidence: C)
2. Exercise stress with nuclear MPI or echocardiography is reasonable
for patients with an intermediate to high pretest probability of
obstructive IHD who have an interpretable ECG and at least moder-
ate physical functioning or no disabling comorbidity (43–53). (Level
of Evidence: B)
3. Pharmacological stress with CMR can be useful for patients with an
intermediate to high pretest probability of obstructive IHD who have
an uninterpretable ECG and at least moderate physical functioning
or no disabling comorbidity (50,54,55). (Level of Evidence: B)
CLASS IIb
1. CCTA might be reasonable for patients with an intermediate pretest
probability of IHD who have at least moderate physical functioning
or no disabling comorbidity (55–63). (Level of Evidence: B)
2. For patients with a low pretest probability of obstructive IHD who do
require testing, standard exercise stress echocardiography might be
reasonable, provided the patient has an interpretable ECG and at
least moderate physical functioning or no disabling comorbidity.
(Level of Evidence: C)
CLASS III: No Benefit
1. Pharmacological stress with nuclear MPI, echocardiography, or
CMR is not recommended for patients who have an interpretable
ECG and at least moderate physical functioning or no disabling
comorbidity (52,64,65). (Level of Evidence: C)
. Exercise stress with nuclear MPI is not recommended as an initial
test in low-risk patients who have an interpretable ECG and at least
moderate physical functioning or no disabling comorbidity. (Level of
Evidence: C)
2.1.3.2. UNABLE TO EXERCISE
CLASS I
1. Pharmacological stress with nuclear MPI or echocardiography is
recommended for patients with an intermediate to high pretest
probability of IHD who are incapable of at least moderate physical
functioning or have disabling comorbidity (43,46,47,49–53). (Level
of Evidence: B)
CLASS IIa
1. Pharmacological stress echocardiography is reasonable for patients
with a low pretest probability of IHD who require testing and are
incapable of at least moderate physical functioning or have dis-
abling comorbidity. (Level of Evidence: C)
. CCTA is reasonable for patients with a low to intermediate pretest
probability of IHD who are incapable of at least moderate physical
functioning or have disabling comorbidity (55–63). (Level of Evi-
dence: B)
. Pharmacological stress CMR is reasonable for patients with an
intermediate to high pretest probability of IHD who are incapable of
at least moderate physical functioning or have disabling comorbid-
ity (50,54,55,66–69). (Level of Evidence: B)
CLASS III: No Benefit
1. Standard exercise ECG testing is not recommended for patients who
have an uninterpretable ECG or are incapable of at least moderate
physical functioning or have disabling comorbidity (43–53,58).(Level of Evidence: C)
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Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The algorithms do not represent a comprehensive list of recommendations (see full guideline
text [2] for all recommendations). †See Table 2 for short-term risk of death or nonfatal MI in patients with UA/NSTEMI. ‡CCTA is reasonable only for patients with intermedi-
te probability of IHD. CCTA indicates computed coronary tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; IHD,schemic heart disease; MI, myocardial infarction; MPI, myocardial perfusion imaging; Pharm, pharmacological; UA, unstable angina; and UA/NSTEMI, unstable angina/non–
T-elevation myocardial infarction.
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CLASS IIa
1. CCTA is reasonable for patients with an intermediate pretest prob-
ability of IHD who a) have continued symptoms with prior normal
test findings, or b) have inconclusive results from prior exercise or
pharmacological stress testing, or c) are unable to undergo stress
with nuclear MPI or echocardiography (70). (Level of Evidence: C)
CLASS IIb
1. For patients with a low to intermediate pretest probability of ob-
structive IHD, noncontrast cardiac computed tomography to deter-
mine the coronary artery calcium score may be considered (71).
Figure 3. Algorithm for Risk Assessment of Patients With SIHD*
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
text [2] for all recommendations). CCTA indicates coronary computed tomography an
ography; LBBB, left bundle-branch block; MPI, myocardial perfusion imaging; and Pha(Level of Evidence: C)3. Risk Assessment: Recommendations
3.1. Advanced Testing: Resting and
Stress Noninvasive Testing
3.1.1. Resting Imaging to Assess Cardiac
Structure and Function
CLASS I
1. Assessment of resting left ventricular (LV) systolic and diastolic
ventricular function and evaluation for abnormalities of myocar-
thms do not represent a comprehensive list of recommendations (see full guideline
phy; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardi-
harmacological.algoridium, heart valves, or pericardium are recommended with the use
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IHD and a prior MI, pathological Q waves, symptoms or signs
suggestive of heart failure, complex ventricular arrhythmias, or an
undiagnosed heart murmur (17,36,37,72,73). (Level of Evidence: B)
CLASS IIb
1. Assessment of cardiac structure and function with resting echocar-
diography may be considered in patients with hypertension or
diabetes mellitus and an abnormal ECG. (Level of Evidence: C)
. Measurement of LV function with radionuclide imaging may be
considered in patients with a prior MI or pathological Q waves,
provided there is no need to evaluate symptoms or signs suggestive
of heart failure, complex ventricular arrhythmias, or an undiagnosed
heart murmur. (Level of Evidence: C)
CLASS III: No Benefit
1. Echocardiography, radionuclide imaging, CMR, and cardiac com-
puted tomography are not recommended for routine assessment of
LV function in patients with a normal ECG, no history of MI, no
symptoms or signs suggestive of heart failure, and no complex
Figure 4. Algorithm for Guideline-Directed Medical Therapy for Pat
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
text [2] for all recommendations). †The use of bile acid sequestrant is relatively con
ides are 500 mg/dL. ‡Dietary supplement niacin must not be used as a substitute
ngiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, ang
ure; CCB, calcium channel blocker; CKD, chronic kidney disease; HDL-C, high-dens
revention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low
ational Heart, Lung, and Blood Institute; and NTG, nitroglycerin.ventricular arrhythmias. (Level of Evidence: C). Routine reassessment (1 year) of LV function with technologies
such as echocardiography radionuclide imaging, CMR, or cardiac
computed tomography is not recommended in patients with no
change in clinical status and for whom no change in therapy is
contemplated. (Level of Evidence: C)
3.1.2. Stress Testing and Advanced Imaging in
Patients With Known SIHD Who Require
Noninvasive Testing for Risk Assessment
See Table 5 for a summary of recommendations from this
ection.
3.1.2.1. RISK ASSESSMENT IN PATIENTS ABLE TO EXERCISE
CLASS I
1. Standard exercise ECG testing is recommended for risk assess-
ment in patients with SIHD who are able to exercise to an
adequate workload and have an interpretable ECG (41,45,74–82).
(Level of Evidence: B)
2. The addition of either nuclear MPI or echocardiography to stan-
With SIHD*
thms do not represent a comprehensive list of recommendations (see full guideline
cated when triglycerides are 200 mg/dL and is contraindicated when triglycer-
rescription niacin.ACCF indicates American College of Cardiology Foundation; ACEI,
in-receptor blocker; ASA, aspirin, ATP III, Adult Treatment Panel 3; BP, blood pres-
protein cholesterol, JNC VII, Seventh Report of the Joint National Committee on
ty lipoprotein cholesterol; LV, left ventricular; MI, myocardial infarction; NHLBI,ients
algori
traindi
for p
iotens
ity lipo
-densidard exercise ECG testing is recommended for risk assessment in
2576 Fihn et al. JACC Vol. 60, No. 24, 2012
Stable Ischemic Heart Disease: Executive Summary December 18, 2012:2564–603patients with SIHD who are able to exercise to an adequate
workload but have an uninterpretable ECG not due to left bundle-
branch block or ventricular pacing (83–87,117–119). (Level of
Evidence: B)
CLASS IIa
1. The addition of either nuclear MPI or echocardiography to standard
exercise ECG testing is reasonable for risk assessment in patients
with SIHD who are able to exercise to an adequate workload and
have an interpretable ECG (88–97). (Level of Evidence: B)
2. CMR with pharmacological stress is reasonable for risk assessment
in patients with SIHD who are able to exercise to an adequate
workload but have an uninterpretable ECG (97–102). (Level of
Evidence: B)
CLASS IIb
1. CCTA may be reasonable for risk assessment in patients with SIHD
who are able to exercise to an adequate workload but have an
Figure 5. Algorithm for Revascularization to Improve Survival of Pa
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
text [2] for all recommendations).uninterpretable ECG (103,104). (Level of Evidence: B)CLASS III: No Benefit
1. Pharmacological stress imaging (nuclear MPI, echocardiography, or
CMR) or CCTA is not recommended for risk assessment in patients
with SIHD who are able to exercise to an adequate workload and
have an interpretable ECG. (Level of Evidence: C)
3.1.2.2. RISK ASSESSMENT IN PATIENTS UNABLE TO EXERCISE
CLASS I
1. Pharmacological stress with either nuclear MPI or echocardiogra-
phy is recommended for risk assessment in patients with SIHD who
are unable to exercise to an adequate workload regardless of
interpretability of ECG (83–86,105–108). (Level of Evidence: B)
CLASS IIa
1. Pharmacological stress CMR is reasonable for risk assessment in
patients with SIHD who are unable to exercise to an adequate
workload regardless of interpretability of ECG (98–102,109). (Level
s With SIHD*
thms do not represent a comprehensive list of recommendations (see full guidelinetient
algoriof Evidence: B)
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with SIHD who are unable to exercise to an adequate workload
regardless of interpretability of ECG (104). (Level of Evidence: C)
3.1.2.3. RISK ASSESSMENT REGARDLESS OF PATIENTS’ ABILITY TO EXERCISE
CLASS I
1. Pharmacological stress with either nuclear MPI or echocardiogra-
phy is recommended for risk assessment in patients with SIHD who
have left bundle-branch block on ECG, regardless of ability to
exercise to an adequate workload (105–108,110). (Level of Evi-
dence: B)
2. Either exercise or pharmacological stress with imaging (nuclear
MPI, echocardiography, or CMR) is recommended for risk assess-
Figure 6. Algorithm for Revascularization to Improve Symptoms of
*Colors correspond to the class of recommendations in the ACCF/AHA Table 1. The
text [2] for all recommendations). CABG indicates coronary artery bypass graft; andment in patients with SIHD who are being considered for revascu-larization of known coronary stenosis of unclear physiological sig-
nificance (84,96,111,112). (Level of Evidence: B)
CLASS IIa
1. CCTA canbeuseful for risk assessment in patientswith SIHDwhohavean
indeterminate result from functional testing (104). (Level of Evidence: C)
CLASS IIb
1. CCTAmight be considered for risk assessment in patients with SIHD
unable to undergo stress imaging or as an alternative to invasive
coronary angiography when functional testing indicates amoderate- to
high-risk result and knowledge of angiographic coronary anatomy is
unknown. (Level of Evidence: C)
CLASS III: No Benefit
1. A request to perform either a) more than 1 stress imaging study or b) a
stress imaging study and a CCTA at the same time is not recommended
ents With SIHD*
thms do not represent a comprehensive list of recommendations (see full guideline
rcutaneous coronary intervention.Pati
algorifor risk assessment in patients with SIHD. (Level of Evidence: C)
3, cardia
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3.2.1. Coronary Angiography as an Initial Testing
Strategy to Assess Risk
CLASS I
1. Patients with SIHD who have survived sudden cardiac death or
potentially life-threatening ventricular arrhythmia should undergo
coronary angiography to assess cardiac risk (121–123). (Level of
Evidence: B)
2. Patients with SIHDwho develop symptoms and signs of heart failure
should be evaluated to determine whether coronary angiography
should be performed for risk assessment (124–127). (Level of
Evidence: B)
3.2.2. Coronary Angiography to Assess Risk After
Initial Workup With Noninvasive Testing
CLASS I
1. Coronary arteriography is recommended for patients with SIHD
whose clinical characteristics and results of noninvasive testing
indicate a high likelihood of severe IHD and when the benefits are
Table 4. Stress Testing and Advanced Imaging for Initial Diagn
Who Require Noninvasive Testing
Test
Exercise
Status
ECG
Interpretable
Able Unable Yes No
Patients able to exercise*
Exercise ECG X X
Exercise with nuclear MPI or Echo X X
Exercise ECG X X
Exercise with nuclear MPI or Echo X X
Pharmacological stress CMR X X
CCTA X Any
Exercise Echo X X
Pharmacological stress with nuclear
MPI, Echo, or CMR
X X
Exercise stress with nuclear MPI X X
Patients unable to exercise
Pharmacological stress with nuclear
MPI or Echo
X Any
Pharmacological stress Echo X Any
CCTA X Any
Pharmacological stress CMR X Any
Exercise ECG X X
Other
CCTA
If patient has any of the following:
a) Continued symptoms with prior
normal test, or
b) Inconclusive exercise or
pharmacological stress, or
c) Unable to undergo stress with MPI
or Echo
Any Any
CAC score Any Any
*Patients are candidates for exercise testing if they are capable of performing at least moderat
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predic
CAC indicates coronary artery calcium; CCTA, cardiac computed tomography angiography; CMR
echocardiography; IHD, ischemic heart disease; LOE, level of evidence; MPI, myocardial perfusideemed to exceed risk (38,72,128–136). (Level of Evidence: C)CLASS IIa
1. Coronary angiography is reasonable to further assess risk in pa-
tients with SIHD who have depressed LV function (ejection fraction
50%) and moderate risk criteria on noninvasive testing with
demonstrable ischemia (137–139). (Level of Evidence: C)
2. Coronary angiography is reasonable to further assess risk in pa-
tients with SIHD and inconclusive prognostic information after
noninvasive testing or in patients for whom noninvasive testing is
contraindicated or inadequate. (Level of Evidence: C)
. Coronary angiography for risk assessment is reasonable for
patients with SIHD who have unsatisfactory quality of life due to
angina, have preserved LV function (ejection fraction50%), and
have intermediate risk criteria on noninvasive testing (140,141).
(Level of Evidence: C)
CLASS III: No Benefit
1. Coronary angiography for risk assessment is not recommended in
patients with SIHD who elect not to undergo revascularization or
who are not candidates for revascularization because of comorbidi-
ties or individual preferences (140,141). (Level of Evidence: B)
2. Coronary angiography is not recommended to further assess risk in
in Patients With Suspected SIHD
retest Probability of IHD
COR LOE Referencesw Intermediate High
X I A (39–42)
X X I B (43–53)
IIa C N/A
X X IIa B (43–53)
X X IIa B (50,54,55)
X IIb B (55–63)
X IIb C N/A
Any III: No Benefit C (52,64,65)
III: No Benefit C N/A
X X I B (43,46,47,49–53)
IIa C N/A
X IIa B (55–63)
X X IIa B (50,54,55,66–69)
Any III: No Benefit C (43–53,58)
X IIa C (70)
IIb C (71)
cal functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.
c magnetic resonance imaging; COR, class of recommendation; ECG, electrocardiogram; Echo,
ging; N/A, not available, and SIHD, stable ischemic heart disease.osis
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(Level of Evidence: B)
3. Coronary angiography is not recommended to assess risk in pa-
tients who are at low risk according to clinical criteria and who have
not undergone noninvasive risk testing. (Level of Evidence: C)
4. Coronary angiography is not recommended to assess risk in asymp-
tomatic patients with no evidence of ischemia on noninvasive
testing. (Level of Evidence: C)
4. Treatment: Recommendations
4.1. Patient Education
CLASS I
1. Patients with SIHD should have an individualized education plan to
optimize care and promote wellness, including:
a. education on the importance of medication adherence for man-
aging symptoms and retarding disease progression (142–144)
Table 5. Using Stress Testing and Advanced Imaging for Patie
Assessment
Test
Exercise
Status
ECG
Interpretable
Able Unable Yes No
Patients able to exercise*
Exercise ECG X X I
Exercise with nuclear MPI or
Echo
X X I
Exercise with nuclear MPI or
Echo
X X IIa
Pharmacological stress CMR X X IIa
CCTA X X IIb
Pharmacological stress
imaging (nuclear MPI, Echo,
CMR) or CCTA
X X III:
Patients unable to exercise
Pharmacological stress with
nuclear MPI or Echo
X Any I
Pharmacological stress CMR X Any IIa
CCTA X Any IIa
Regardless of patient’s ability to exercise
Pharmacological stress with
nuclear MPI or Echo
Any X I
Exercise/pharmacological
stress with nuclear MPI,
Echo, or CMR
Any Any I
CCTA Any Any IIa
CCTA Any Any IIb
Requests to perform multiple
cardiac imaging or stress
studies at the same time
Any Any III:
CCTA indicates cardiac computed tomography angiography; CMR, cardiac magnetic resonance
bundle-branch block; LOE, level of evidence; MPI, myocardial perfusion imaging; and N/A, not a
*Patients are candidates for exercise testing if they are capable of performing at least modera
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predic(Level of Evidence: C);b. an explanation of medication management and cardiovascular
risk reduction strategies in a manner that respects the patient’s
level of understanding, reading comprehension, and ethnicity
(8,145–149) (Level of Evidence: B);
c. a comprehensive review of all therapeutic options (8,146–149)
(Level of Evidence: B);
d. a description of appropriate levels of exercise, with encourage-
ment to maintain recommended levels of daily physical activity
(8,150–153) (Level of Evidence: C);
e. introduction to self-monitoring skills (150,152,153) (Level of
Evidence: C); and
f. information on how to recognize worsening cardiovascular symp-
toms and take appropriate action. (Level of Evidence: C)
2. Patients with SIHD should be educated about the following lifestyle
elements that could influence prognosis: weight control, mainte-
nance of a body mass index of 18.5 to 24.9 kg/m2, and mainte-
nance of a waist circumference less than 102 cm (40 inches) in
ith Known SIHD Who Require Noninvasive Testing for Risk
LOE References Additional Considerations
B (41,45,74–82)
B (83–87,117–119) Abnormalities other than LBBB or
ventricular pacing
B (88–97)
B (97–102)
B (103,104)
nefit C N/A
B (83–86,105–108)
B (98–102,109)
C (104) Without prior stress test
B (105–108,110) LBBB present
B (84,96,111,112) Known coronary stenosis of unclear
physiological significance being
considered for revascularization
C N/A Indeterminate result from
functional testing
C N/A Unable to undergo stress imaging
or as alternative to coronary
catheterization when functional
testing indicates moderate to
high risk and angiographic
coronary anatomy is unknown
nefit C N/A
; COR, class of recommendation; ECG, electrocardiogram; Echo, echocardiography; LBBB, left
.
ical functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.nts W
COR
No Be
No Be
imaging
vailablemen and less than 88 cm (35 inches) in women (less for certain
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pressure control (24,158); smoking cessation and avoidance of expo-
sure to secondhand smoke (8,159,160); and individualized medical,
nutrition, and lifestyle changes for patients with diabetes mellitus to
supplement diabetes treatment goals and education (161). (Level of
Evidence: C)
CLASS IIa
1. It is reasonable to educate patients with SIHD about
a. adherence to a diet that is low in saturated fat, cholesterol, and
trans fat; high in fresh fruits, whole grains, and vegetables; and
reduced in sodium intake, with cultural and ethnic preferences
incorporated (8,23,24,162,163) (Level of Evidence: B);
b. common symptoms of stress and depression to minimize stress-
related angina symptoms (164) (Level of Evidence: C);
c. comprehensive behavioral approaches for the management of
stress and depression (165–168) (Level of Evidence: C); and
d. evaluation and treatment of major depressive disorder when
indicated (142,165,167,169,170,173–175). (Level of Evi-
dence: B)
4.2. Guideline-Directed Medical Therapy
4.2.1. Risk Factor Modification
4.2.1.1. LIPID MANAGEMENT
CLASS I
1. Lifestyle modifications, including daily physical activity and weight
management, are strongly recommended for all patients with SIHD
(23,176). (Level of Evidence: B)
. Dietary therapy for all patients should include reduced intake of
saturated fats (to 7% of total calories), trans fatty acids (to 1%
of total calories), and cholesterol (to 200 mg/d) (23,177–180).
(Level of Evidence: B)
3. In addition to therapeutic lifestyle changes, a moderate or high dose
of a statin therapy should be prescribed, in the absence of contra-
indications or documented adverse effects (23,163,181–183).
(Level of Evidence: A)
CLASS IIa
1. For patients who do not tolerate statins, low-density lipoprotein-
cholesterol–lowering therapy with bile acid sequestrants,* niacin,†
or both is reasonable (184,186,187). (Level of Evidence: B)
4.2.1.2. BLOOD PRESSURE MANAGEMENT
CLASS I
1. All patients should be counseled about the need for lifestyle modi-
fication: weight control; increased physical activity; alcohol moder-
ation; sodium reduction; and emphasis on increased consumption
of fresh fruits, vegetables, and low-fat dairy products (24,188–196).
(Level of Evidence: B)
2. In patients with SIHD with blood pressure 140/90 mm Hg or
higher, antihypertensive drug therapy should be instituted in
addition to or after a trial of lifestyle modifications (197–202).
(Level of Evidence: A)
3. The specific medications used for treatment of high blood pressure
should be based on specific patient characteristics and may include
angiotensin-converting enzyme (ACE) inhibitors and/or beta block-
*The use of bile acid sequestrant is relatively contraindicated when triglycerides are
200 mg/dL and is contraindicated when triglycerides are 500 mg/dL.
†Dietary supplement niacin must not be used as a substitute for prescription niacin.ers, with addition of other drugs, such as thiazide diuretics or
calcium channel blockers, if needed to achieve a goal blood pres-
sure of less than 140/90 mm Hg (203,204). (Level of Evidence: B)
4.2.1.3. DIABETES MANAGEMENT
CLASS IIa
1. For selected individual patients, such as those with a short duration
of diabetes mellitus and a long life expectancy, a goal hemoglobin
A1c of 7% or less is reasonable (205–207). (Level of Evidence: B)
2. A goal hemoglobin A1c between 7% and 9% is reasonable for
certain patients according to age, history of hypoglycemia, presence
of microvascular or macrovascular complications, or presence of
coexisting medical conditions (208,209). (Level of Evidence: C)
CLASS IIb
1. Initiation of pharmacotherapy interventions to achieve target hemoglo-
bin A1c might be reasonable (161,210–219). (Level of Evidence: A)
CLASS III: Harm
1. Therapy with rosiglitazone should not be initiated in patients with
SIHD (220,221). (Level of Evidence: C)
4.2.1.4. PHYSICAL ACTIVITY
CLASS I
1. For all patients, the clinician should encourage 30 to 60 minutes of
moderate-intensity aerobic activity, such as brisk walking, at least 5
days and preferably 7 days per week, supplemented by an increase
in daily lifestyle activities (e.g., walking breaks at work, gardening,
household work) to improve cardiorespiratory fitness and move
patients out of the least-fit, least-active, high-risk cohort (bottom
20%) (222–224). (Level of Evidence: B)
. For all patients, risk assessment with a physical activity history
and/or an exercise test is recommended to guide prognosis and
prescription (225–228). (Level of Evidence: B)
. Medically supervised programs (cardiac rehabilitation) and physician-
directed, home-based programs are recommended for at-risk patients
at first diagnosis (222,229, 230). (Level of Evidence: A)
CLASS IIa
1. It is reasonable for the clinician to recommend complementary
resistance training at least 2 days per week (231,232). (Level of
Evidence: C)
4.2.1.5. WEIGHT MANAGEMENT
CLASS I
1. Body mass index and/or waist circumference should be assessed at
every visit, and the clinician should consistently encourage weight
maintenance or reduction through an appropriate balance of life-
style physical activity, structured exercise, caloric intake, and formal
behavioral programs when indicated to maintain or achieve a body
mass index between 18.5 and 24.9 kg/m2 and a waist circumfer-
ence less than 102 cm (40 inches) in men and less than 88 cm (35
inches) in women (less for certain racial groups) (154,233–241).
(Level of Evidence: B)
2. The initial goal of weight loss therapy should be to reduce body weight
by approximately 5% to 10% from baseline. With success, further
weight loss can be attempted if indicated. (Level of Evidence: C)
4.2.1.6. SMOKING CESSATION COUNSELING
CLASS I
1. Smoking cessation and avoidance of exposure to environmentaltobacco smoke at work and home should be encouraged for all
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pharmacotherapy are recommended, as is a stepwise strategy for
smoking cessation (Ask, Advise, Assess, Assist, Arrange, Avoid)
(242–244). (Level of Evidence: B)
4.2.1.7. MANAGEMENT OF PSYCHOLOGICAL FACTORS
CLASS IIa
1. It is reasonable to consider screening SIHD patients for depression
and to refer or treat when indicated (162,165,169,245–248). (Level
of Evidence: B)
CLASS IIb
1. Treatment of depression has not been shown to improve cardiovas-
cular disease outcomes but might be reasonable for its other
clinical benefits (165,173,249). (Level of Evidence: C)
4.2.1.8. ALCOHOL CONSUMPTION
CLASS IIb
1. In patients with SIHD who use alcohol, it might be reasonable for
nonpregnant women to have 1 drink (4 ounces of wine, 12 ounces
of beer, or 1 ounce of spirits) a day and for men to have 1 or 2 drinks
a day, unless alcohol is contraindicated (such as in patients with a
history of alcohol abuse or dependence or with liver disease)
(250–252). (Level of Evidence: C)
4.2.1.9. AVOIDING EXPOSURE TO AIR POLLUTION
CLASS IIa
1. It is reasonable for patients with SIHD to avoid exposure to in-
creased air pollution to reduce the risk of cardiovascular events
(253–256). (Level of Evidence: C)
4.2.2. Additional Medical Therapy to
Prevent MI and Death
4.2.2.1. ANTIPLATELET THERAPY
CLASS I
1. Treatment with aspirin 75 to 162 mg daily should be continued
indefinitely in the absence of contraindications in patients with SIHD
(257,258). (Level of Evidence: A)
2. Treatment with clopidogrel is reasonable when aspirin is contrain-
dicated in patients with SIHD (259). (Level of Evidence: B)
CLASS IIb
1. Treatment with aspirin 75 to 162 mg daily and clopidogrel 75 mg
daily might be reasonable in certain high-risk patients with SIHD
(260). (Level of Evidence: B)
CLASS III: No Benefit
1. Dipyridamole is not recommended as antiplatelet therapy for pa-
tients with SIHD (261–263). (Level of Evidence: B)
4.2.2.2. BETA-BLOCKER THERAPY
CLASS I
1. Beta-blocker therapy should be started and continued for 3 years in
all patients with normal LV function after MI or ACS (264–266).
(Level of Evidence: B)
2. Beta-blocker therapy should be used in all patients with LV systolic
dysfunction (ejection fraction 40%) with heart failure or prior MI,
unless contraindicated. (Use should be limited to carvedilol, meto-
prolol succinate, or bisoprolol, which have been shown to reduce
risk of death.) (267–271) (Level of Evidence: A)CLASS IIb
1. Beta blockers may be considered as chronic therapy for all other
patients with coronary or other vascular disease. (Level of Evidence: C)
4.2.2.3. RENIN-ANGIOTENSIN-ALDOSTERONE BLOCKER THERAPY
CLASS I
1. ACE inhibitors should be prescribed in all patients with SIHD who
also have hypertension, diabetes mellitus, LV ejection fraction 40%
or less, or chronic kidney disease, unless contraindicated (113–
116,120). (Level of Evidence: A)
2. Angiotensin-receptor blockers are recommended for patients with
SIHD who have hypertension, diabetes mellitus, LV systolic dysfunc-
tion, or chronic kidney disease and have indications for, but are
intolerant of, ACE inhibitors (272–274). (Level of Evidence: A)
CLASS IIa
1. Treatment with an ACE inhibitor is reasonable in patients with both
SIHD and other vascular disease (275,276). (Level of Evidence: B)
. It is reasonable to use angiotensin-receptor blockers in other pa-
tients who are ACE inhibitor intolerant (277). (Level of Evidence: C)
4.2.2.4. INFLUENZA VACCINATION
CLASS I
1. An annual influenza vaccine is recommended for patients with SIHD
(278–282). (Level of Evidence: B)
4.2.2.5. ADDITIONAL THERAPY TO REDUCE RISK OF MI AND DEATH
CLASS III: No Benefit
1. Estrogen therapy is not recommended in postmenopausal women
with SIHD with the intent of reducing cardiovascular risk or improv-
ing clinical outcomes (283–286). (Level of Evidence: A)
2. Vitamin C, vitamin E, and beta-carotene supplementation are not
recommended with the intent of reducing cardiovascular risk or
improving clinical outcomes in patients with SIHD (181,287–291).
(Level of Evidence: A)
3. Treatment of elevated homocysteine with folate or vitamins B6 and
B12 is not recommended with the intent of reducing cardiovascular
risk or improving clinical outcomes in patients with SIHD (292–295).
(Level of Evidence: A)
4. Chelation therapy is not recommended with the intent of improving
symptoms or reducing cardiovascular risk in patients with SIHD
(296–299). (Level of Evidence: C)
5. Treatment with garlic, coenzyme Q10, selenium, or chromium is not
recommended with the intent of reducing cardiovascular risk or
improving clinical outcomes in patients with SIHD. (Level of Evi-
dence: C)
4.2.3. Medical Therapy for Relief of Symptoms
4.2.3.1. USE OF ANTI-ISCHEMIC MEDICATIONS
CLASS I
1. Beta blockers should be prescribed as initial therapy for relief of
symptoms in patients with SIHD (264,300,301). (Level of Evidence: B)
. Calcium channel blockers or long-acting nitrates should be pre-
scribed for relief of symptoms when beta blockers are contraindi-
cated or cause unacceptable side effects in patients with SIHD
(302–304). (Level of Evidence: B)
. Calcium channel blockers or long-acting nitrates, in combination
with beta blockers, should be prescribed for relief of symptoms
when initial treatment with beta blockers is unsuccessful in patients
with SIHD (304). (Level of Evidence: B)
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immediate relief of angina in patients with SIHD (305–307). (Level
of Evidence: B)
CLASS IIa
1. Treatment with a long-acting nondihydropyridine calcium channel
blocker (verapamil or diltiazem) instead of a beta blocker as initial
therapy for relief of symptoms is reasonable in patients with SIHD
(304). (Level of Evidence: B)
2. Ranolazine can be useful when prescribed as a substitute for beta
blockers for relief of symptoms in patients with SIHD if initial
treatment with beta blockers leads to unacceptable side effects or
is ineffective or if initial treatment with beta blockers is contraindi-
cated (308). (Level of Evidence: B)
. Ranolazine in combination with beta blockers can be useful when
prescribed for relief of symptoms when initial treatment with beta
blockers is not successful in patients with SIHD (309,310). (Level of
Evidence: A)
4.2.4. Alternative Therapies for Relief of Symptoms in
Patients With Refractory Angina
CLASS IIb
1. Enhanced external counterpulsation may be considered for relief of
refractory angina in patients with SIHD (311). (Level of Evidence: B)
. Spinal cord stimulation may be considered for relief of refractory
angina in patients with SIHD (312,313). (Level of Evidence: C)
. Transmyocardial revascularization may be considered for relief of
refractory angina in patients with SIHD (314–316). (Level of Evi-
dence: B)
CLASS III: No Benefit
1. Acupuncture should not be used for the purpose of improving
symptoms or reducing cardiovascular risk in patients with SIHD
(317,318). (Level of Evidence: C)
5. CAD Revascularization:
Recommendations
Table 6 and Table 7 provide summaries of recommenda-
tions from this section.
5.1. Heart Team Approach to
Revascularization Decisions
CLASS I
1. A Heart Team approach to revascularization is recommended in
patients with unprotected left main or complex CAD (319–321).
(Level of Evidence: C)
CLASS IIa
1. Calculation of the STS and SYNTAX scores is reasonable in patients
with unprotected left main and complex CAD (321–327). (Level of
Evidence: B)
5.2. Revascularization to Improve Survival
Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is recommended for patients with signif-
icant (50% diameter stenosis) left main coronary artery stenosis
(328–334). (Level of Evidence: B)CLASS IIa
1. PCI to improve survival is reasonable as an alternative to CABG in
selected stable patients with significant (50% diameter stenosis)
unprotected left main CAD with: 1) anatomic conditions associated
with a low risk of PCI procedural complications and a high likelihood
of good long-term outcome (e.g., a low SYNTAX score [22], ostial
or trunk left main CAD); and 2) clinical characteristics that predict a
significantly increased risk of adverse surgical outcomes (e.g.,
STS-predicted risk of operative mortality5%) (322,324,325,335–
353). (Level of Evidence: B)
2. PCI to improve survival is reasonable in patients with unstable
angina/non–ST-elevation MI when an unprotected left main coro-
nary artery is the culprit lesion and the patient is not a candidate for
CABG (325,340,342–344,349–352,354). (Level of Evidence: B)
. PCI to improve survival is reasonable in patients with acute ST-
elevation MI when an unprotected left main coronary artery is the
culprit lesion, distal coronary flow is less than TIMI (Thrombolysis In
Myocardial Infarction) grade 3, and PCI can be performed more
rapidly and safely than CABG (337,355,356). (Level of Evidence: C)
CLASS IIb
1. PCI to improve survival may be reasonable as an alternative to
CABG in selected stable patients with significant (50% diameter
stenosis) unprotected left main CAD with: a) anatomic conditions
associated with a low to intermediate risk of PCI procedural com-
plications and an intermediate to high likelihood of good long-term
outcome (e.g., low–intermediate SYNTAX score of 33, bifurcation
left main CAD); and b) clinical characteristics that predict an
increased risk of adverse surgical outcomes (e.g., moderate–
severe chronic obstructive pulmonary disease, disability from
previous stroke, or previous cardiac surgery; STS-predicted risk of
operative mortality 2%) (322,324,325,335–353,357). (Level
of Evidence: B)
CLASS III: Harm
1. PCI to improve survival should not be performed in stable
patients with significant (50% diameter stenosis) unprotected
left main CAD who have unfavorable anatomy for PCI and who
are good candidates for CABG (322,324,325,328–336). (Level of
Evidence: B)
Non–Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is beneficial in patients with significant
(70% diameter) stenoses in 3 major coronary arteries (with or
without involvement of the proximal LAD artery) or in the proxi-
mal LAD artery plus 1 other major coronary artery (125,330,334,
358–360). (Level of Evidence: B)
2. CABG or PCI to improve survival is beneficial in survivors of sudden
cardiac death with presumed ischemia-mediated ventricular tachy-
cardia caused by significant (70% diameter) stenosis in a major
coronary artery. (CABG Level of Evidence: B [122,378,379]; PCI
Level of Evidence: C [378])
CLASS IIa
1. CABG to improve survival is reasonable in patients with signifi-
cant (70% diameter) stenoses in 2 major coronary arteries with
severe or extensive myocardial ischemia (e.g., high-risk criteria
on stress testing, abnormal intracoronary hemodynamic evalua-
tion, or 20% perfusion defect by myocardial perfusion stress
imaging) or target vessels supplying a large area of viable
myocardium (363–366). (Level of Evidence: B)
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Anatomic Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (319–321)
CABG and PCI IIa—Calculation of STS and SYNTAX scores B (321–327)
UPLM*
CABG I B (328–334)
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural
complications and a high likelihood of good long-term outcome (e.g., a low
SYNTAX score of 22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of adverse
surgical outcomes (e.g., STS-predicted risk of operative mortality 5%)
B (322,324,325,335–353)
IIa—For UA/NSTEMI if not a CABG candidate B (325,340,342–344,349–352,354)
IIa—For STEMI when distal coronary flow is TIMI flow grade 3 and PCI can be
performed more rapidly and safely than CABG
C (337,355,356)
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI
procedural complications and an intermediate to high likelihood of good long-
term outcome (e.g., low-intermediate SYNTAX score of 33, bifurcation left
main CAD)
● Clinical characteristics that predict an increased risk of adverse surgical
outcomes (e.g., moderate—severe COPD, disability from prior stroke, or prior
cardiac surgery; STS-predicted operative mortality 2%)
B (322,324,325,335–353,357)
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable
anatomy for PCI and who are good candidates for CABG
B (322,324,325,328–336)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (125,330,334,358–360)
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel
CAD (e.g., SYNTAX score 22) who are good candidates for CABG.
B (336,353,360–362)
PCI IIb—Of uncertain benefit B (140,330,353,358,360)
2-vessel disease with proximal LAD artery disease*
CABG I B (125,330,334,358–360)
PCI IIb—Of uncertain benefit B (140,330,358,360)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (363–366)
IIb—Of uncertain benefit without extensive ischemia C (360)
PCI IIb—Of uncertain benefit B (140,330,358,360)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B (334,360,367,368)
PCI IIb—Of uncertain benefit B (140,330,358,360)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (141,334,358,363, 364,369–372)
PCI III: Harm B (141,334,358,363,364, 369–372)
LV dysfunction
CABG IIa—EF 35% to 50% B (139,334,373–376)
CABG IIb—EF 35% without significant left main CAD B (127,139,334,373–377)
PCI Insufficient data N/A
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (122,378,379)
PCI I C (378)
No anatomic or physiological criteria for revascularization
CABG III: Harm B (141,334,358,363, 364,369–372)
PCI III: Harm B (141,334,358,363,364,369–372)
*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI (365,380,381,381–386) (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior
descending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not available; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI,
ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial
Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
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LV systolic dysfunction (ejection fraction 35% to 50%) and significant
(70% diameter stenosis) multivessel CAD or proximal LAD coronary
artery stenosis, when viable myocardium is present in the region of
intended revascularization (139,334,373–376). (Level of Evidence: B)
. CABG with a left internal mammary artery graft to improve survival
is reasonable in patients with significant (70% diameter) stenosis
in the proximal LAD artery and evidence of extensive ischemia
(334,360,367,368). (Level of Evidence: B)
. It is reasonable to choose CABG over PCI to improve survival in
patients with complex 3-vessel CAD (e.g., SYNTAX score 22), with
or without involvement of the proximal LAD artery who are good
candidates for CABG (336,353,360–362). (Level of Evidence: B)
. CABG is probably recommended in preference to PCI to improve
survival in patients with multivessel CAD and diabetes mellitus,
particularly if a left internal mammary artery graft can be anasto-
mosed to the LAD artery (365,380,381–386). (Level of Evidence: B)
CLASS IIb
1. The usefulness of CABG to improve survival is uncertain in patients
with significant (70%) diameter stenoses in 2 major coronary
arteries not involving the proximal LAD artery and without extensive
ischemia (360). (Level of Evidence: C)
. The usefulness of PCI to improve survival is uncertain in patients
with 2- or 3-vessel CAD (with or without involvement of the proximal
LAD artery) or 1-vessel proximal LAD disease (140,330,358,360).
(Level of Evidence: B)
. CABG might be considered with the primary or sole intent of
improving survival in patients with SIHD with severe LV systolic
dysfunction (ejection fraction35%) whether or not viable myocar-
dium is present (127,139,334,373–377). (Level of Evidence: B)
. The usefulness of CABG or PCI to improve survival is uncertain in
patients with previous CABG and extensive anterior wall ischemia
on noninvasive testing (397–401,408–411). (Level of Evidence: B)
CLASS III: Harm
1. CABG or PCI should not be performed with the primary or sole
intent to improve survival in patients with SIHD with 1 or more
coronary stenoses that are not anatomically or functionally
Table 7. Revascularization to Improve Symptoms With Signific
hysiological (FFR <0.80) Coronary Artery Stenoses
Clinical Setting
1 significant stenoses amenable to revascularization and
unacceptable angina despite GDMT
1 significant stenoses and unacceptable angina in whom GDMT
cannot be implemented because of medication contraindications,
adverse effects, or patient preferences
Previous CABG with 1 significant stenoses associated with
ischemia and unacceptable angina despite GDMT
Complex 3-vessel CAD (e.g., SYNTAX score >22) with or without
involvement of the proximal LAD artery and a good candidate for
CABG
Viable ischemic myocardium that is perfused by coronary arteries that
are not amenable to grafting
No anatomic or physiological criteria for revascularization
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recomm
N/A, not available; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutanesignificant (e.g., 70% diameter non–left main coronary arterystenosis, fractional flow reserve 0.80, no or only mild ischemia
on noninvasive testing), involve only the left circumflex or right
coronary artery, or subtend only a small area of viable myocar-
dium (141,334,358,363,364,369–372). (Level of Evidence: B)
5.3. Revascularization to Improve Symptoms
CLASS I
1. CABG or PCI to improve symptoms is beneficial in patients with 1 or
more significant (70% diameter) coronary artery stenoses ame-
nable to revascularization and unacceptable angina despite GDMT
(140,387–393,395,396,412). (Level of Evidence: A)
CLASS IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1
or more significant (70% diameter) coronary artery stenoses and
unacceptable angina for whom GDMT cannot be implemented
because of medication contraindications, adverse effects, or patient
preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous
CABG, 1 or more significant (70% diameter) coronary artery
stenoses associated with ischemia, and unacceptable angina de-
spite GDMT (397,399,400). (Level of Evidence: C)
. It is reasonable to choose CABG over PCI to improve symptoms in
patients with complex 3-vessel CAD (e.g., SYNTAX score22), with or
without involvement of the proximal LAD artery, who are good candi-
dates for CABG (325,336,353,360–362). (Level of Evidence: B)
CLASS IIb
1. CABG to improve symptoms might be reasonable for patients with
previous CABG, 1 or more significant (70% diameter) coronary
artery stenoses not amenable to PCI, and unacceptable angina
despite GDMT (401). (Level of Evidence: C)
. Transmyocardial revascularization performed as an adjunct to
CABG to improve symptoms may be reasonable in patients with
viable ischemicmyocardium that is perfused by arteries that are not
amenable to grafting (402–406). (Level of Evidence: B)
CLASS III: Harm
1. CABG or PCI to improve symptoms should not be performed in
patients who do not meet anatomic (50% diameter left main or
natomic (>50% Left Main or >70% Non–Left Main CAD) or
COR LOE References
1—CABG A (140,387–396)
1—PCI
IIa—CABG C N/A
IIa—PCI C N/A
IIa—PCI C (397–400)
IIb—CABG C (401)
IIa—CABG preferred over PCI B (353,360–362)
IIb—TMR as an adjunct to CABG B (402–406)
III: Harm—CABG C N/A
III: Harm—PCI C N/A
n; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; LOE, level of evidence;
ronary Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial revascularization.ant A70% non–left main stenosis diameter) or physiological (e.g.,
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(Level of Evidence: C)
5.4. Dual Antiplatelet Therapy Compliance and
Stent Thrombosis
CLASS III: Harm
1. PCI with coronary stenting (bare-metal stent or drug-eluting stent)
should not be performed if the patient is not likely to be able to
tolerate and comply with dual antiplatelet therapy for the appropri-
ate duration of treatment based on the type of stent implanted
(414–417). (Level of Evidence: B)
5.5. Hybrid Coronary Revascularization
CLASS IIa
1. Hybrid coronary revascularization (defined as the planned combina-
tion of left internal mammary artery–to–LAD artery grafting and PCI
of1 non-LAD coronary arteries) is reasonable in patients with 1 or
more of the following (418–424) (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily calcified proxi-
mal aorta or poor target vessels for CABG (but amenable to PCI);
b. Lack of suitable graft conduits;
Table 8. Follow-Up Noninvasive Testing in Patients With Known
Not Consistent With UA
Test
Exercise
Status
ECG
Interpretable
CAble Unable Yes No
Patients able to exercise*
Exercise ECG X X I
Exercise with nuclear MPI or
Echo
X X I
Exercise with nuclear MPI or
Echo
X Any IIa
Pharmacological stress
nuclear MPI/Echo/CMR
X X III: No
Patients unable to exercise
Pharmacological stress
nuclear MPI or Echo
X Any I
Pharmacological stress CMR X Any IIa
Exercise ECG X X III: No
Irrespective of ability to exercise
CCTA Any Any IIb
CCTA Any Any IIb
CCTA Any Any III: No
*Patients are candidates for exercise testing if they are capable of performing at least moderat
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predicCABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography angiograph
Echo, echocardiography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not availablec. Unfavorable LAD artery for PCI (i.e., excessive vessel tortuosity or
chronic total occlusion).
CLASS IIb
1. Hybrid coronary revascularization (defined as the planned com-
bination of left internal mammary artery–to–LAD artery grafting
and PCI of 1 non-LAD coronary arteries) may be reasonable as
an alternative to multivessel PCI or CABG in an attempt to
improve the overall risk–benefit ratio of the procedures. (Level of
Evidence: C)
6. Patient Follow-Up: Monitoring of
Symptoms and Antianginal Therapy:
Recommendations
6.1. Clinical Evaluation, Echocardiography During
Routine, Periodic Follow-Up
CLASS I
1. Patients with SIHD should receive periodic follow-up, at least annu-
ally, that includes all of the following (Level of Evidence: C):
a. Assessment of symptoms and clinical function;
b. Surveillance for complications of SIHD, including heart failure
and arrhythmias;
D: New, Recurrent, or Worsening Symptoms
LOE References Additional Considerations
B (39–42)
B (69,95,96,102,
141,364,
426–435)
B (436,437) ● Prior requirement for imaging with
exercise
● Known or at high risk for multivessel
disease
fit C (438)
B (43,46,47,49–53)
B (98,99,101)
fit C N/A
B (439–443) Patency of CABG or coronary stent 3 mm
diameter
B (55,58,439) In the absence of known moderate or
severe calcification and intent to assess
coronary stent 3 mm in diameter
fit B (439–443) Known moderate or severe native coronary
calcification or assessment of coronary
stent 3 mm in diameter in patients
who have new or worsening symptoms
not consistent with UA
cal functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.SIH
OR
Bene
Bene
Bene
e physi
ted may; CMR, cardiac magnetic resonance; COR, class of recommendation; ECG, electrocardiogram;
; SIHD, stable ischemic heart disease; and UA, unstable angina.
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d. Assessment of the adequacy of and adherence to recommended
lifestyle changes and medical therapy.
2. Assessment of LV ejection fraction and segmental wall motion by
echocardiography or radionuclide imaging is recommended in pa-
tients with new or worsening heart failure or evidence of intervening
MI by history or ECG. (Level of Evidence: C)
CLASS IIb
1. Periodic screening for important comorbidities that are prevalent in
patients with SIHD, including diabetes mellitus, depression, and
chronic kidney disease might be reasonable. (Level of Evidence: C)
2. A resting 12-lead ECG at 1-year or longer intervals between studies
in patients with stable symptoms might be reasonable. (Level of
Evidence: C)
CLASS III: No Benefit
1. Measurement of LV function with a technology such as echocardi-
ography or radionuclide imaging is not recommended for routine
periodic reassessment of patients who have not had a change in
clinical status or who are at low risk of adverse cardiovascular
events (425). (Level of Evidence: C)
6.2. Noninvasive Testing in Known SIHD
6.2.1. Follow-Up Noninvasive Testing in Patients
With Known SIHD: New, Recurrent, or Worsening
Symptoms Not Consistent With Unstable Angina
See Table 8 for a summary of recommendations from this
ection.
Table 9. Noninvasive Testing in Known SIHD: Asymptomatic (o
Test
Exercise Status
ECG
Interpretable
Pretes
Able* Unable Yes No
Exercise or pharmacological
stress with nuclear MPI,
Echo, or CMR at 2-y
intervals
X X Prior evid
ischem
for rec
event.
listed
consid
Exercise ECG at 1-y
intervals
X X
Exercise ECG X X No prior
ischem
high r
cardia
Exercise or pharmacological
stress with nuclear MPI,
Echo, or CMR or CCTA
Any Any
*Patients are candidates for exercise testing if they are capable of performing at least moderat
living) and have no disabling comorbidity. Patients should be able to achieve 85% of age-predic
CABG indicates coronary artery bypass graft surgery; CCTA, cardiac computed tomography
tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocard
percutaneous coronary intervention; and SIHD, stable ischemic heart disease.6.2.1.1. PATIENTS ABLE TO EXERCISE
CLASS I
1. Standard exercise ECG testing is recommended in patients with
known SIHD who have new or worsening symptoms not consistent
with UA and who have a) at least moderate physical functioning and
no disabling comorbidity and b) an interpretable ECG (39–42).
(Level of Evidence: B)
2. Exercise with nuclear MPI or echocardiography is recommended in
patients with known SIHD who have new or worsening symptoms
not consistent with UA and who have a) at least moderate physical
functioning or no disabling comorbidity but b) an uninterpretable
ECG (69,95,96,102,141,364,426–435). (Level of Evidence: B)
CLASS IIa
1. Exercise with nuclear MPI or echocardiography is reasonable in
patients with known SIHD who have new or worsening symptoms
not consistent with UA and who have a) at least moderate physical
functioning and no disabling comorbidity, b) previously required
imaging with exercise stress, or c) known multivessel disease or
high risk for multivessel disease (436,437). (Level of Evidence: B)
CLASS III: No Benefit
1. Pharmacological stress imaging with nuclear MPI, echocardiogra-
phy, or CMR is not recommended in patients with known SIHD who
have new or worsening symptoms not consistent with UA and who
are capable of at least moderate physical functioning or have no
disabling comorbidity (438). (Level of Evidence: C)
6.2.1.2. PATIENTS UNABLE TO EXERCISE
CLASS I
1. Pharmacological stress imaging with nuclear MPI or echocardiog-
raphy is recommended in patients with known SIHD who have new
ble Symptoms)
ability of
ia COR LOE References
Additional
Considerations
of silent
high risk
t cardiac
s criteria
itional
ns.
IIa C (10,13,20) a) Unable to exercise to
adequate workload
or
b) Uninterpretable ECG
or
c) History of incomplete
coronary
revascularization
IIb C N/A a) Prior evidence of
silent ischemia OR
b) At high risk for
recurrent cardiac
event
ce of silent
d not at
recurrent
t.
IIb C N/A For annual surveillance
III: No
Benefit
C (10,13,20) a) 5-y intervals after
CABG, or
b) 2-y intervals after
PCI
cal functioning (i.e., moderate household, yard, or recreational work and most activities of daily
ximum heart rate.
aphy; CMR, coronary magnetic resonance; COR, class of recommendation; CCTA, computedr Sta
t Prob
Ischem
ence
ia or
urren
Meet
in add
eratio
Any
eviden
ia an
isk of
c even
Any
e physi
ted ma
angiogriography; LOE, level of evidence; MPI, myocardial perfusion imaging; N/A, not available; PCI,
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pable of at least moderate physical functioning or have disabling
comorbidity (43,46,47,49–53). (Level of Evidence: B)
CLASS IIa
1. Pharmacological stress imaging with CMR is reasonable in patients
with known SIHD who have new or worsening symptoms not con-
sistent with UA and who are incapable of at least moderate physical
functioning or have disabling comorbidity (98,99,101). (Level of
Evidence: B)
CLASS III: No Benefit
1. Standard exercise ECG testing should not be performed in patients
with known SIHD who have new or worsening symptoms not con-
sistent with UA and who a) are incapable of at least moderate
physical functioning or have disabling comorbidity or b) have an
uninterpretable ECG. (Level of Evidence: C)
6.2.1.3. IRRESPECTIVE OF ABILITY TO EXERCISE
CLASS IIb
1. CCTA for assessment of patency of CABG or of coronary stents 3
mm or larger in diameter might be reasonable in patients with
known SIHD who have new or worsening symptoms not consistent
with UA, irrespective of ability to exercise (439–443). (Level of
Evidence: B)
2. CCTA might be reasonable in patients with known SIHD who have
new or worsening symptoms not consistent with UA, irrespective of
ability to exercise, in the absence of known moderate or severe
calcification or if the CCTA is intended to assess coronary stents less
than 3 mm in diameter (55,58,439). (Level of Evidence: B)
CLASS III: No Benefit
1. CCTA should not be performed for assessment of native coronary
arteries with known moderate or severe calcification or with coro-
nary stents less than 3mm in diameter in patients with known SIHD
who have new or worsening symptoms not consistent with UA,
irrespective of ability to exercise (439–443). (Level of Evidence: B)
6.2.2. Noninvasive Testing in Known SIHD—
Asymptomatic (or Stable Symptoms)
See Table 9 for a summary of recommendations from this
ection.
CLASS IIa
1. Nuclear MPI, echocardiography, or CMR with either exercise or
pharmacological stress can be useful for follow-up assessment
at 2-year or longer intervals in patients with SIHD with prior
evidence of silent ischemia or who are at high risk for a recurrent
cardiac event and a) are unable to exercise to an adequate
workload, b) have an uninterpretable ECG, or c) have a history of
incomplete coronary revascularization (10,13,20). (Level of Evi-
dence: C)
CLASS IIb
1. Standard exercise ECG testing performed at 1-year or longer inter-
vals might be considered for follow-up assessment in patients with
SIHD who have had prior evidence of silent ischemia or are at high
risk for a recurrent cardiac event and are able to exercise to an
adequate workload and have an interpretable ECG. (Level of Evi-
dence: C)
2. In patients who have no new or worsening symptoms or no prior
evidence of silent ischemia and are not at high risk for a recurrentcardiac event, the usefulness of annual surveillance exercise ECG
testing is not well established. (Level of Evidence: C)
CLASS III: No Benefit
1. Nuclear MPI, echocardiography, or CMR, with either exercise or
pharmacological stress or CCTA, is not recommended for follow-up
assessment in patients with SIHD, if performed more frequently
than at a) 5-year intervals after CABG or b) 2-year intervals after PCI
(10,13,20). (Level of Evidence: C)
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